Formulation of vaccine adjuvant muramyldipeptides (MDP). 1. Characterization of amorphous and crystalline forms of a muramyldipeptide analogue.
A relatively nonhygroscopic crystalline form of the glycopeptide, N-acetylmuramyl-L-alpha-aminobutyryl-D-isoglutamine (I), containing approximately one molecule of water was prepared from amorphous material. The crystalline material, consisting of a mixture of the alpha and beta anomers, exhibited better physical and chemical stability than the lyophilized amorphous material. The alpha/beta-anomer ratios of I in both the crystalline and the amorphous state were approximately equal but different from that in solution.
Chan
T W
TW
Institute of Pharmaceutical Sciences, Syntex Research, Palo Alto, California 94304.
Becker
A
A
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000032:analysis*; D000276:Adjuvants, Immunologic; D055598:Chemical Phenomena; D002621:Chemistry; D002851:Chromatography, High Pressure Liquid; D003460:Crystallization; D005612:Freeze Drying; D013696:Temperature; D013818:Thermogravimetry; D014961:X-Ray Diffraction
D000276:Adjuvants, Immunologic; D000119:Acetylmuramyl-Alanyl-Isoglutamine